文献速递血栓与止血

罗扎诺利珠单抗抑制FcRn治疗成人免疫性血小板减少症:两项随机双盲安慰剂对照3期研究及其开放标签扩展研究

Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension.
PubMed 文献 · Br J Haematol · 2024-11-18

报告罗扎诺利珠单抗在持续性/慢性ITP成人中的3期研究(TP0003、TP0006)及52周开放标签扩展研究。双盲研究因运营延迟与治疗格局变化提前终止,仅21/12例(TP0003)和20/10例(TP0006)随机至罗扎诺利珠单抗或安慰剂。罗扎诺利珠单抗组达到DCMPR例数多于安慰剂组,每周给药似乎比每2周给药更有效。

要点

  • 罗扎诺利珠单抗组DCMPR:TP0003为4/21 vs 安慰剂0;TP0006为1/20 vs 安慰剂0。
  • 第8天血小板≥50×10^9/L:TP0003罗扎诺利珠单抗组52.4%(安慰剂2/12);TP0006为45.0%(安慰剂1/10)。
  • 开放标签扩展中每周给药期间血小板升高得以维持;每周给药似乎比每2周给药更有效。

核心结论

  • 罗扎诺利珠单抗组达到DCMPR的患者例数多于安慰剂组:TP0003为4/21 vs 0,TP0006为1/20 vs 0。
  • 开放标签扩展中每周给药期间血小板升高得以维持。
  • 每周给药似乎比每2周给药更有效。

研究设计与样本

  • 两项24周随机、双盲、安慰剂对照3期研究(TP0003;TP0006)及52周开放标签扩展研究。
  • 双盲研究中罗扎诺利珠单抗组与安慰剂组随机例数:TP0003为21例与12例,TP0006为20例与10例。
  • 开放标签扩展研究纳入43例患者:42例起始每2周给药,其中21例后来转为每周给药。

主要发现

  • 罗扎诺利珠单抗组DCMPR:TP0003为4/21,TP0006为1/20;安慰剂组均为0。
  • 第8天血小板≥50×10^9/L:TP0003罗扎诺利珠单抗组52.4%(安慰剂2/12),TP0006为45.0%(安慰剂1/10)。
  • 总体最常见的治疗中出现的不良事件为头痛、发热和恶心,与既往所见一致。

关键数值与推荐

  • 主要终点为双盲研究第13-25周期间持续8/12周血小板≥50×10^9/L的持久临床有意义血小板反应(DCMPR)。
  • 罗扎诺利珠单抗为单克隆IgG4抗FcRn抗体,阻断IgG再循环并降低IgG水平。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 运营延迟和不断演变的ITP治疗格局导致申办方提前终止这些研究。
  • 因此仅21例和12例(TP0003)以及20例和10例(TP0006)患者被随机至罗扎诺利珠单抗或安慰剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary immune thrombocytopenia (ITP) is an antiplatelet-antibody-mediated disorder with accelerated platelet clearance and decreased platelet production. Rozanolixizumab, a monoclonal IgG4 anti-FcRn antibody, blocks IgG recycling and decreases IgG levels. We report efficacy and safety of rozanolixizumab in adults with persistent/chronic ITP in 24-week phase 3 studies (TP0003; TP0006), and their 52-week open-label extension (OLE). Primary end-point was durable clinically meaningful platelet response (DCMPR) of ≥50 × 109/L for 8/12 weeks during Weeks 13-25 in the double-blind studies. Operational delays and evolving ITP treatment landscape led the sponsor to terminate these studies early; thus, only 21 and 12 (TP0003) and 20 and 10 (TP0006) patients were randomised to rozanolixizumab or placebo. Forty-three patients enrolled in the OLE: 42 started on every 2-week dosing; 21 later switched to weekly dosing. More rozanolixizumab-treated than placebo-treated patients achieved DCMPR: 4/21 versus 0 (TP0003) and 1/20 versus 0 (TP0006). Platelet increases to ≥50 × 109/L were observed on Day 8 in 52.4% (TP0003; 2/12 placebo) and 45.0% (TP0006; 1/10 placebo) of rozanolixizumab-treated patients. OLE platelet increases were maintained while on weekly dosing. The most frequent treatment-emergent adverse events overall were headache, pyrexia and nausea, as seen previously. Weekly dosing appears more efficacious than every 2-week dosing.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Cooper N, Bussel JB, Kaźmierczak M, et al. Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension. Br J Haematol. 2024. PMID: 39552477. doi:10.1111/bjh.19858

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。